The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).
 
Patrick O'Shea
No Relationships to Disclose
 
Matthew Labriola
No Relationships to Disclose
 
Lauren Howard
Consulting or Advisory Role - Tempus
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - BeiGene; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
 
Mark Fleming
No Relationships to Disclose
 
Elisabeth Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Gilead Sciences; Novartis; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo Inc. (Inst); Eisai (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Sanofi
Other Relationship - Caris Centers of Excellence
 
Ronald Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Compass Therapeutics; GlaxoSmithKline; ImmnityBio; Novartis; Urogen pharma; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Novartis; Nymox
Speakers' Bureau - Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); ESSA (Inst); Exosome Diagnostics (Inst); Francis Medical (Inst); Genomic Health (Inst); Janssen Oncology (Inst); Lantheus Medical Imaging (Inst); Lilly (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); POINT Biopharma (Inst); Propella Therapeutics (Inst)
 
Brian Lewis
No Relationships to Disclose
 
Michael Humeniuk
No Relationships to Disclose
 
Michael Harrison
No Relationships to Disclose
 
Julie Kephart
No Relationships to Disclose
 
Julia Hurrelbrink
No Relationships to Disclose
 
Julia Rasmussen
Research Funding - Flatiron Health
 
Kellie Shobe
No Relationships to Disclose
 
Monika Anand
No Relationships to Disclose
 
Marco Reyes-Martinez
No Relationships to Disclose
 
Steven Patierno
Stock and Other Ownership Interests - Curaleaf; Theralogix; Therasplice
Honoraria - Gilead Health Equity
Consulting or Advisory Role - AstraZeneca
Research Funding - Gilead Sciences
Patents, Royalties, Other Intellectual Property - Duke University
 
Jennifer Freedman
Stock and Other Ownership Interests - Therasplice
Research Funding - Janssen
 
Andrew Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Cytogen; Exelixis; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Daniel George
Leadership - Capio BioSciences
Stock and Other Ownership Interests - Pfizer
Honoraria - American Association for Cancer Research; Astellas Pharma; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Merck; Millennium Medical Publishing; Myovant Sciences; Novartis; OncLive; Pfizer; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Novartis; Pfizer